Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23969120 | 0.88 | FURIN (0.33) | C3AR1 | |
| SCHEMBL24714725 | 0.88 | FURIN (0.33) | C3AR1 | |
| SCHEMBL22853936 | 0.82 | FURIN (0.36) | — | |
| SCHEMBL24172621 | 0.82 | C3AR1 (0.36) | C3AR1CTDSP1 | |
| SCHEMBL23872238 | 0.81 | C3AR1 (0.36) | C3AR1CTDSP1 | |
| SCHEMBL22215553 | 0.81 | C3AR1 (0.36) | C3AR1CTDSP1 | |
| SCHEMBL23872313 | 0.79 | C3AR1 (0.35) | C3AR1CTDSP1 | |
| SCHEMBL24172604 | 0.79 | C3AR1 (0.35) | C3AR1CTDSP1 | |
| SCHEMBL24086402 | 0.78 | FURIN (0.32) | C3AR1 | |
| SCHEMBL21788004 | 0.78 | FURIN (0.36) | C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180529-B2 | Alpha-v beta-6 integrin ligands and uses thereof | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20190248832-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248832-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | ITGAV, ITGA6, ITGB6 | C3AR1 514/4885CTDSP1 4384/4885 |
| US-11180529-B2 | Alpha-v beta-6 integrin ligands and uses thereof | ITGAV, ITGA6, ITGB6 | C3AR1 514/4885CTDSP1 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.